BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36804053)

  • 1. Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial.
    Merle P; Blanc JF; Edeline J; Le Malicot K; Allaire M; Assenat E; Guarssifi M; Bouattour M; Péron JM; Laurent-Puig P; Levrero M; Costentin C; Guiu B; Sokol H; Tougeron D; Aparicio T; Nault JC; Phelip JM
    Dig Liver Dis; 2023 Apr; 55(4):464-470. PubMed ID: 36804053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
    Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
    BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
    Ben Khaled N; Seidensticker M; Ricke J; Mayerle J; Oehrle B; Rössler D; Teupser D; Ehmer U; Bitzer M; Waldschmidt D; Fuchs M; Reuken PA; Lange CM; Wege H; Kandulski A; Dechêne A; Venerito M; Berres ML; Luedde T; Kubisch I; Reiter FP; De Toni EN
    Future Oncol; 2022 Apr; 18(12):1423-1435. PubMed ID: 35081747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
    J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis.
    Changez MIK; Khan M; Uzair M; Tahir MF; Mohsin M; Hussain AF; Saqib V; Molani MK; Ahmed AH; Khalid S
    J Gastrointest Cancer; 2024 Mar; 55(1):467-481. PubMed ID: 38095799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
    Nakagawa M; Inoue M; Ogasawara S; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kikuchi Y; Kogure T; Yumita S; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Taida T; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Shinozaki M; Kato J; Kato N
    Cancer; 2023 Feb; 129(4):590-599. PubMed ID: 36426410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.
    Gao X; Zhao R; Ma H; Zuo S
    BMC Cancer; 2023 Jul; 23(1):635. PubMed ID: 37415136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
    Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ;
    Lancet; 2019 Jun; 393(10189):2404-2415. PubMed ID: 31079938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
    Zeng Q; Klein C; Caruso S; Maille P; Allende DS; Mínguez B; Iavarone M; Ningarhari M; Casadei-Gardini A; Pedica F; Rimini M; Perbellini R; Boulagnon-Rombi C; Heurgué A; Maggioni M; Rela M; Vij M; Baulande S; Legoix P; Lameiras S; ; Bruges L; Gnemmi V; Nault JC; Campani C; Rhee H; Park YN; Iñarrairaegui M; Garcia-Porrero G; Argemi J; Sangro B; D'Alessio A; Scheiner B; Pinato DJ; Pinter M; Paradis V; Beaufrère A; Peter S; Rimassa L; Di Tommaso L; Vogel A; Michalak S; Boursier J; Loménie N; Ziol M; Calderaro J
    Lancet Oncol; 2023 Dec; 24(12):1411-1422. PubMed ID: 37951222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
    Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
    Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
    Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
    Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
    JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.